Tests

View a selection of ARUP's hemostasis and thrombosis testing.

Resources

View forms and documents related to our testing.

FAQs

Hemostasis/Thrombosis frequently asked questions.

Experts

Visit the experts section to see a list of our specialists.

Welcome to JM’s Hemostasis/Thrombosis Laboratory

Our Hemostasis & Thrombosis Laboratory offers a wide array of testing for hematologic and platelet disorders. The Hemostasis lab provides routine and esoteric testing for bleeding and thrombotic disorders. The division is supported by R&D scientists who are focused on new test development. Medical directors are board certified in their areas of expertise. They are available to answer questions regarding test results and consult with clients on difficult to diagnose cases. We are committed to applying scientific advances to promote efficiency, enhance patient care and improve clinical utility.

Medical Importance

The Screening tests of hemostasis were developed to help identify patients with haemostatics defects that could cause excessive bleeding. Screening tests are available for each of the three phases of Haemostasis: coagulation (fibrin clot formation), platelet plug formation, and fibrinolysis. In general, the tests are sufficiently sensitive to be abnormal in most patients with a haemostatics defect severe enough to cause bleeding. However, they occasionally are overly sensitive and may be abnormal due to disorders that do not cause hemorrhage.

These tests are used very commonly in clinical medicine, both to help predict hemorrhage at surgery and to identify specific defects in patients with a history of excessive bruising or bleeding. Based on this information, appropriate therapy can be administered, such as fresh frozen plasma or clotting factor concentrates for coagulation defects, platelet transfusions or von Willebrand factor concentrates for platelet function defects or antifibrinolytic agents for systemic fibrinolysis.

Objectives

  1. Given values for the PT/INR, PTT, TT (thrombin time), fibrinogen concentration, and platelet count, be able to construct an appropriate differential diagnosis of possible disorders giving rise to these abnormalities.
  2. Given values for various clotting factor concentrations, be able to predict which screening tests of coagulation will be abnormal.
  3. Be able to explain how a 1:1 mixing study can distinguish a clotting factor deficiency from an inhibitor of coagulation.
  4. Be able to explain the utility and derivation of the INR.
  5. Be able to compare and contrast three tests of platelet function - bleeding time, PFA-100, and platelet aggregation studies.
  6. Be able to diagram the formation of the D-dimer and explain its utility in diagnosis venous thromboembolic disease.

JM’s Mission

Our mission is to provide a multidisciplinary approach to the diagnosis and management of patients with hemorrhagic and thromboembolic disorders, conduct clinical, translational, and basic research studies; and teach physicians, students, and other healthcare providers about this specialty.

Our programs focus on patients with complex hemorrhagic and thromboembolic disorders; anticoagulation management issues, and provision of peri-operative and peri-procedural support. Specialists in maternal-fetal medicine, pediatrics, genetic counseling, interventional radiology and surgery who have a particular interest in patients with these disorders are also members of the Center.

Title

  • Small Title
  • Small Title
  • Small Title
  • Small Title

Title

  • Small Title
  • Small Title
  • Small Title
  • Small Title